Abstract
Background Among patients with aortic stenosis, severe ventricular remodeling can limit the augmentation of flow with exertion, even after valve intervention. While long-term mortality risk has been shown be elevated in this patient population, the effect on quality of life (QoL) improvement has not been studied. Our objective was to determine the effect of severe ventricular remodeling on QoL outcomes after transcatheter aortic valve replacement (TAVR).
Methods All patients undergoing TAVR from 2011-2021 at our institution were included. Groups were divided according to guideline-recommended cutoffs for left ventricular (LV) wall thickness. Normal or mild wall thickness was designated as non-remodeled (NR) and moderate/severe wall thickness defined the remodeled group (REM). The Kansas City Cardiomyopathy Questionnaire (KCCQ) was utilized to assess QoL and the primary outcome was KCCQ change <5 from baseline to 30 days and 1 year.
Results We analyzed 679 patients (NR: N=389, REM: N=290). Baseline KCCQ overall score [OS] trended higher in the NR group (60.1 vs. 56.6, p=0.053). Echocardiographic baseline differed between NR and REM by septal thickness (1.12 cm vs. 1.44 cm, p<0.001), posterior wall thickness (1.08 cm vs. 1.33 cm, p<0.001), and LV internal diastolic diameter (4.34 cm vs. 4.19 cm, p=0.006). The primary outcome was similar between NR and REM at 30 days (31.6% vs. 28.6%, p=0.449) and at 1 year (27.7% vs. 21.5%, p=0.217). NR and REM experienced similar proportions of worsening or no change, small, moderate, and large improvements in KCCQ score (<5, 5-10, 10-19, ≥20, respectively). Both groups experienced similar domain score changes and NYHA improvement. At one year, NR demonstrated greater reduction in 5MWT time compared to REM (−1.98 s vs. -0.2 s, p=0.028). A subgroup analysis of REM patients did not reveal interaction with cavity size, stroke volume, mitral regurgitation, E/A ratio, valvulo-arterial impedance, or hyperdynamic ejection fraction.
Conclusions Patients with severe ventricular remodeling and aortic stenosis have similar QoL changes after intervention compared to patients without significant remodeling. Findings from this study support aortic valve intervention irrespective of ventricular remodeling.
What is Known?
Ventricular remodeling occurs due to aortic stenosis, limiting cardiac output even after valve replacement.
The effect of ventricular remodeling on quality of life after TAVR is unknown.
What the Study Adds
Quality of life improvement occurred in the majority of patients undergoing TAVR, with and without severe ventricular remodeling, and to a similar degree regardless of remodeling.
From a quality-of-life perspective, TAVR should remain a viable consideration for patients with severe ventricular remodeling
Competing Interest Statement
Toby Rogers reports being a consultant and physician proctor for Medtronic, Edwards Lifesciences, and Boston Scientific; serving on the advisory boards of Medtronic and Boston Scientific; and holding equity interest in Transmural Systems. William S. Weintraub reports receiving research support from Amarin Corporation, Lexicon Pharmaceuticals, and the National Institutes of Health; and being a consultant for Amarin Corporation, AstraZeneca, Janssen, Lexicon Pharmaceuticals, SC Pharma, and The Medicines Company. Ron Waksman reports serving on the advisory boards of Abbott Vascular, Boston Scientific, Medtronic, Philips IGT, and Pi-Cardia Ltd.; being a consultant for Abbott Vascular, Biotronik, Boston Scientific, Cordis, Medtronic, Philips IGT, Pi-Cardia Ltd., Swiss Interventional Systems/SIS Medical AG, Transmural Systems Inc., and Venous MedTech; receiving institutional grant support from Amgen, Biotronik, Boston Scientific, Chiesi, Medtronic, and Philips IGT; and being an investor in MedAlliance and Transmural Systems. All other authors ? None.
Clinical Trial
This is a retrospective observational study of patients at our institution and, therefore, was not registered as a clinical trial.
Funding Statement
No external funding was provided for the research reported in this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the MedStar Washington Hospital Center Institutional Review Board, and all patients provided written informed consent before participation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on reasonable request to the corresponding author.
Abbreviations and Nonstandard Acronyms
- AS
- aortic stenosis
- EF
- ejection fraction
- KCCQ
- Kansas City Cardiomyopathy Questionnair
- LV
- left ventricular
- LVH
- left ventricular hypertrophy
- NR
- non-remodeled group
- NYHA
- New York Heart Association
- QoL
- quality of life
- REM
- remodeled
- TAVR
- transcatheter aortic valve replacement
